Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)

Last updated: May 4, 2012
Sponsor: Takeda
Overall Status: Completed

Phase

3

Condition

Gastroesophageal Reflux Disease (Gerd)

Gastroparesis

Gastric Ulcers

Treatment

N/A

Clinical Study ID

NCT00261300
BY1023/VMG-708
  • All Genders

Study Summary

Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD might occur when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the esophagus. GERD is one of the most common medical disorders, with estimates of up to 50% of adults reporting reflux symptoms. One of the main symptoms of GERD is heartburn. It occurs when the acidic content from the stomach touches the lining of the esophagus, causing a burning sensation in the chest or throat. Proton pump inhibitors such as pantoprazole can relieve symptoms of GERD and peptic ulcers in a large proportion of patients.

Additionally, long-term treatment with proton pump inhibitors may be needed for patients with chronic ulcer disease not caused by H. pylori (H. pylori is a stomach-dwelling bacteria which is often associated with ulcers in the stomach or duodenum).

The aim of the study is to evaluate the long-term effect of pantoprazole in patients with chronic gastric acid-related complaints. The study duration consists of a 5-year treatment period. Pantoprazole will be administered once daily. The study will provide further data on long-term safety, tolerability, and efficacy of pantoprazole.

Eligibility Criteria

Inclusion

Main Inclusion Criteria:

  • Patients who completed ALTANA Pharma study BY1023/FK3006 (long-term clinical trialregarding efficacy and tolerability of Pantoprazole in patients not responding totreatment with H2-receptor antagonists or omeprazole)

  • Written informed consent

Exclusion

Main Exclusion Criteria:

  • Concomitant diseases

  • Pregnant or nursing female patients; female patients of childbearing potential who arenot using reliable contraception

Study Design

Total Participants: 100
Study Start date:
October 01, 2000
Estimated Completion Date:
July 31, 2008

Connect with a study center

  • Altana Pharma/Nycomed

    Hannover, 30659
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.